

ALLERGAN INC  
Form SC 14D9/A  
June 30, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 14D-9**  
**SOLICITATION/RECOMMENDATION STATEMENT**  
**UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**(AMENDMENT NO. 2)**

**Allergan, Inc.**  
**(Name of Subject Company)**

**Allergan, Inc.**  
**(Name of Person Filing Statement)**

**Common Stock, \$0.01 par value**  
**(Title of Class of Securities)**

**018490102**

Edgar Filing: ALLERGAN INC - Form SC 14D9/A

(CUSIP Number of Class of Securities)

**Matthew J. Maletta, Esq.**

**Vice President,**

**Associate General Counsel and Secretary**

**2525 Dupont Drive**

**Irvine, California 92612**

**(714) 246-4500**

**(Name, address and telephone number of person authorized to receive notices and communications on behalf of the person filing statement)**

*With copies to:*

**Paul D. Tosetti, Esq.**

**David A. Katz, Esq.**

**Cary K. Hyden, Esq.**

**Daniel A. Neff, Esq.**

**Michael A. Treska, Esq.**

**Wachtell, Lipton, Rosen & Katz**

**Latham & Watkins LLP**

**51 West 52nd Street**

**650 Town Center Drive, 20th Floor**

**New York, New York 10019**

**Costa Mesa, California 92626**

**(212) 403-1000**

**(714) 540-1235**

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Amendment No. 2 to Schedule 14D-9 amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended from time to time, the **Statement** ) originally filed by Allergan, Inc., a Delaware corporation ( **Allergan** ), with the Securities and Exchange Commission (the **SEC** ) on June 23, 2014, as amended by Amendment No. 1, filed with the SEC on June 23, 2014, relating to the unsolicited offer by Valeant Pharmaceuticals International, Inc., a corporation continued under the laws of the Province of British Columbia ( **Valeant** ), through its wholly owned subsidiary, AGMS Inc., a Delaware corporation, to exchange each outstanding share of Allergan's common stock, par value \$0.01 per share (including the associated preferred stock purchase rights, the **Shares** ), at the election of the holder of the Shares, for either 0.83 common shares of Valeant, no par value (the **Valeant Common Shares** ) and \$72.00 in cash, or an equal amount of cash or number of Valeant Common Shares, upon the terms and subject to the election and proration procedures and other conditions set forth in its Preliminary Prospectus/Offer to Exchange, dated June 18, 2014 (as amended or supplemented from time to time), and the related letter of election and transmittal. Except as specifically noted herein, the information set forth in the Statement remains unchanged. Capitalized terms used and not defined herein shall have the meanings assigned to such terms in the Schedule 14D-9. This Amendment is being filed to reflect certain updates as reflected below:

**Item 8. Additional Information**

Item 8, Additional Information is hereby amended and supplemented by adding the paragraph set forth below as the last paragraph under the heading *Litigation PS Fund 1, LLC Action* :

On June 27, 2014, Allergan and PS Fund 1 entered into a stipulation agreeing to dismiss the litigation. Before and after PS Fund 1 initiated the litigation, Allergan had invited PS Fund 1 and Pershing Square to discuss their concerns related to the Rights Agreement and Bylaws.

**ITEM 9. EXHIBITS.**

Item 9 of the Statement is hereby amended and supplemented by adding the following exhibit:

- (a)(7) Stipulation and [Proposed] Order Regarding Application of Allergan's Rights Plan and Dismissal Without Prejudice, dated June 27, 2014

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

**ALLERGAN, INC.**

By: /s/ Matthew J. Maletta  
Name: Matthew J. Maletta  
Title: Vice President,  
Associate General Counsel and  
Secretary

Dated: June 27, 2014

**Exhibit Index**

**Exhibit**

**Description of Exhibit**

(a)(7) Stipulation and [Proposed] Order Regarding Application of Allergan's Rights Plan and Dismissal Without Prejudice, dated June 27, 2014